We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ImmunoGen Inc | NASDAQ:IMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 31.235 | 32.80 | 29.67 | 0 | 01:00:00 |
From Apr 2022 to Apr 2024
By Colin Kellaher
ImmunoGen Inc. on Monday said the U.S. Food and Drug Administration granted priority review to its application for mirvetuximab soravtansine monotherapy in certain patients with ovarian cancer.
The Waltham, Mass., biotechnology company is seeking approval of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have previously received one to three systemic treatments.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. ImmunoGen said the agency set a target action date of Nov. 28 for the application.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 23, 2022 06:54 ET (10:54 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year ImmunoGen Chart |
1 Month ImmunoGen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
